Royalty Report: Drugs, Disease, Gastrointestinal – Collection: 263902


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 10


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 10

Primary Industries

  • Drugs
  • Disease
  • Gastrointestinal
  • Pharmaceuticals
  • Bacterial Infection
  • Therapeutic
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 263902

License Grant
The Licensor of Germany grants, in respect of the Licensor Patents, the Licensor IP and the Licensor Product Data the sole and exclusive royalty bearing right and license to use the same and to develop, use and Exploit the Product throughout the Territory and a non-exclusive right and license to manufacture and have manufactured the Product in any part of the world for Exploitation in the Territory only.
License Property
The licensed property is a pellet formulation of mesalamine.  

The name of the product is Salofalk® 500 mg, Granu-Stix®.   Salofalk Granu-Stix delivers the therapeutically active antiinflammatory agent mesalamine (5-aminosalicylic acid or 5-ASA) to the distal ileum and colon by means of dual-release granules.

The patents include Pellet formulation for the treatment of the intestinal tract,  and, Pellet-type formulation intended for treating the intestinal tract.

Field of Use
The field of use is for the treatment of acute episodes and the maintenance of remission of ulcerative colitis.
Ulcerative colitis (UC) is a disease that affects your large intestine, or colon. It causes irritation and swelling called inflammation. … UC is a type of inflammatory bowel disease, but it's different from other diseases with similar symptoms, like Crohn's disease or irritable bowel syndrome.

IPSCIO Record ID: 264191

License Grant
The Company executed a license agreement with the University for a worldwide, exclusive license to manufacture, market, sell and sublicense Extracellular Matrix Hydrogel.
License Property
ExtraCellular Matrix Hydrogel (“ECMH”), targets the treatment of multiple gastrointestinal diseases, including Ulcerative Colitis, Crohn’s Disease, and Rectal Mucositis.
Field of Use
This agreement pertains to the drug industry with a field of use limited to human and animal colonic and small intestine therapeutic indications.

ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.
Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur.

IPSCIO Record ID: 266736

License Grant
Licensor, a non-profit hospital, grants to Licensee to the extent of the Licensed Territory an exclusive license under the patent rights to make, have made, use, sell and have sold, and import licensed products in the Licensed Field, with the right to sub license.

Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.

License Property
Licensor owns US Patent application for Methods of Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth, and, US Patent entitled Methods of Diagnosing or Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth.

Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.

Field of Use
The Licensed Field means the use of rifaximin to treat any disease state claimed in whole or in part by a valid claim contained in the patent rights. It is the intent of the parties that the Licensed Field will not include any use of the Patent Rights or Licensed Technology for diagnostic purposes.

Rifaximin is an antibiotic used to treat traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy.

IPSCIO Record ID: 256198

License Grant
For the Licensor Pre-Clinical Know-How License and Patent Rights License, and, Data Delivery,  The German Licensor grants an exclusive right and license, including the right to grant sublicenses, under the Licensor Pre-Clinical Know-How and Patent Rights to:
–   Develop, use, Commercialize, sell, offer for sale and import Product in the Licensee Territory, and,
–   subject, as between Licensee and the Third Party, to the terms of the Third Party/Licensee Agreements, have Product made by Third Party, make and have made Product.

For the Cross-Licenses, Pre-Clinical Data and Clinical Data Sharing, Licensor grants:
–   an exclusive right and license, including the right to grant sublicenses, to and under Pre-Clinical Data and Clinical Data that is or becomes during the term of this Agreement owned or Controlled by Licensor to develop, use, import, sell, offer for sale, and Commercialize Product in the Field in the Licensee Territory, and subject, as between Licensee and the Third Party, to the terms of the Third Party/Licensee Agreements, have Product made by the Third Party, make and have made Product; and
–   consents to Licensees right of reference and use of such Pre-Clinical Data and Clinical Data in connection with Regulatory Filings in the Licensee Territory.

License Property
The Product shall mean any pharmaceutical or medicinal product containing Trichuris suis ova (TSO) as the active ingredient, incorporated into any formulation or delivery system, intended for use in the prevention, treatment or cure of any human disease or condition.

Trichuris suis ova shall mean the ova or eggs of the Trichuris suis worm.

The U.S. Patent Application Nos. 12/594,074 and 12/993,517 are related to the Product.

Field of Use
The Field of use shall mean the prevention, treatment or cure of Crohns disease and/or ulcerative colitis.

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of your digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition.
Ulcerative colitis is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucous.

IPSCIO Record ID: 233469

License Grant
The Licensor of England grants to Licensee of Bermuda the exclusive right and license under the Patent Rights, the Technical Information and Manufacturing Technology to develop, have developed, make, have made, use, sell and have sold Products within the Territory. Notwithstanding the foregoing, Licensor may authorize a Specific Third Party, its Affiliates and successors to manufacture Balsalazide within the Territory solely for sale and use outside the Territory.
License Property
The patents and technology are related to Balsalazide, or to prodrugs, analogs or isomers thereof or improvements of any of the foregoing, obtained in any country within the Territory.

Balsalazide means 5-[4(2-Carboxyethelcarbamoyl)-phenylazo] – salicylic acid disodium salt dihydrate.

Products means products incorporating Balsalazide, whether or not such products are covered by the Patent Rights, or any other material whose manufacture, use or sale by an unlicensed third party would constitute an infringement of any Valid Claim included within the Patent Rights.

Field of Use
The product is used for gastrointestinal disease.

First marketed product, Colazal, was the first new molecular entity approved in 10 years by the FDA for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the FDA for this indication in seven years.  Ulcerative colitis is a chronic form of inflammatory bowel disease characterized by inflammation of the lining of the colon. Symptoms of active ulcerative colitis include rectal bleeding, abdominal pain, increased stool frequency, loss of appetite, fever and weight loss.

IPSCIO Record ID: 7344

License Grant
The Licensee entered into an exclusive License Agreement (with a right to subLicense) with the Licensor, a nonprofit medical research facility, for the rights to novel modulators of sphingosine phosphate receptors, including modulators to the S1P1R.
License Property
The technology Licensed covers RPC1063.

RMS:  RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).

RPC1063 for the treatment of UC: IBD is comprised of two chronic, autoimmune, GI inflammatory disorders: UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.

Field of Use
RPC1063, is being developed as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD).

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.

IPSCIO Record ID: 30510

License Grant
Licensee of Canada acquired exclusive rights to develop and market in North America a patented 4-gram rectal gel formulation of mesalamine for the treatment of active distal ulcerative colitis from an Italian Licensor.
Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 210693

License Grant
The Licensor granted the Licensee an exclusive worldwide license to develop, manufacture and commercialize PTG-200 and other IL-23R compounds covered by our patent rights that meet certain requirements for all indications of inflammatory bowel disease,IBD, including CD – Crohns disease and UC – ulcerative colitis.
License Property
The Licensor is a biopharmaceutical company with a proprietary technology platform utilized to discover and develop oral targeted therapy-based peptide drugs including PTG-200 for treatments including the treatment of CD and UC.
Field of Use
The Licensee entered the collaboration agreement for the development, manufacture and commercialization of PTG-200 worldwide.

IPSCIO Record ID: 57817

License Grant
On May 2, 2010, the Licensee received a worldwide, exclusive and perpetual license to use patents and know how relating to BEKINDAâ„¢ from the previous Licensor, a U.S. company, who is now out of business.  On March 7, 2014, the Company entered into a licensing agreement with a U.S. University to secure certain patent rights related to the drug candidate. The Company therefore terminated the agreement with the U.S. company and licensed the patents directly from the U.S. university, the original owner of the patents. Under the agreement, the Company agreed to pay the U.S. university certain future payments.
License Property
BEKINDAâ„¢ is a once-daily controlled release oral formulation of ondansetron, a leading member of the family of 5HT-3 serotonin receptor inhibitors for the treatment of gastroenteritis and gastritis.

Gastroenteritis, also known as infectious diarrhea, is inflammation of the gastrointestinal tract—the stomach and small intestine.
Gastritis is inflammation of the lining of the stomach.

Field of Use
The biopharmaceutical company is focused on the development and acquisition of late clinical-stage, proprietary, orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases and cancer.

Gastroenteritis and gastritis – 24 mg strength

Irritable Bowel Syndrome with Diarrhea (IBS-D) – 12 mg strength

Prevention of chemotherapy and radiotherapy induced nausea and vomiting (oncology support) – 24 mg strength

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.